Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WGc-0201
- Development stage
- Phase 1
- Lead developer
- Chengdu Weisijin Biopharmaceutical Technology
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
WGc-0201 is an investigational mRNA therapeutic vaccine being developed for the treatment of HBV-related diseases, specifically chronic hepatitis B infection and hepatocellular carcinoma (HCC). It encodes hepatitis B virus (HBV)-related antigens (notably protein X/HBX), and is formulated as a lipid nanoparticle (LNP) injection. The mechanism involves immune activation and inhibition of HBX, aiming to elicit robust antigen-specific immune responses and overcome HBV-driven tumor or infection by immunostimulatory means. Early preclinical and clinical data suggest durable disease control and strong immunogenicity. It is being developed using proprietary mRNA and LNP platforms, with early-phase trials led by Chinese developers in heavily HBV-burdened populations[1][6][7][10][13][18].
- Other names
- HBx-based mRNA vaccineHBx-based mRNA immunotherapyHBx-encoding mRNA-LNP vaccine
02
Targets
HBx (Hepatitis B virus X protein)
Beyond the preview
Go deeper on WGc-0201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WGc-0201.